A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).
Qfitlia (fitusiran), developed by French company Sanofi, is a subcutaneous treatment that helps prevent bleeding. The approval in the U.S. applies to patients aged 12 and older who have hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.
The treatment is administered once every other month, while several other therapies are given weekly. This is expected to simplify the daily life of hemophilia patients.
BREAKING